$30M Transforms Ebola Vaccine for Africa's Hardest-Hit Areas

The world just took a major step toward ending Ebola outbreaks before they spiral out of control.

The Coalition for Epidemic Preparedness Innovations announced it will invest up to $30 million to redesign how we manufacture and store the Ebola vaccine. The goal is simple but powerful: make it affordable and accessible for the African communities that need it most.

Right now, the existing Ebola vaccine works incredibly well at stopping the Zaire strain, the deadliest form of the virus that kills about half the people it infects. But there's a massive problem with getting it where it needs to go.

The current vaccine must be frozen at negative 70 degrees Celsius, colder than most home freezers can reach. That makes it nearly impossible to transport and store in remote villages where Ebola typically strikes. Plus, the complex manufacturing process drives up costs and limits how much can be produced during emergencies.

Pharmaceutical company MSD will partner with Hilleman Laboratories to completely update the production process. The breakthrough improvement will allow the new version to be stored at normal refrigerator temperatures between 2 and 8 degrees Celsius for several months.

That single change could save countless lives. Healthcare workers in rural clinics across Africa will be able to keep the vaccine on hand without expensive freezers or constant cold chain logistics.

The updated manufacturing will also increase how many doses can be produced and slash the price for low and middle income countries. During large outbreaks, vaccine makers will be able to scale up production quickly to stop the virus from spreading.

Clinical trials will begin in African countries where the current vaccine is already approved. Researchers will confirm that the updated version produces the same immune response, ensuring it protects just as well as the original.

The Ripple Effect

This project represents a decade of global determination paying off. When Ebola devastated West Africa between 2014 and 2016, the world had no vaccine and limited treatment options. Scientists and health organizations rallied together and developed the first effective vaccine in record time.

Now that same spirit of collaboration is making sure frontline healthcare workers and at-risk communities can actually access that protection. The Democratic Republic of Congo faced another outbreak in 2025, a stark reminder that Ebola hasn't disappeared.

Richard Hatchett, CEO of the Coalition, captured the significance perfectly: the world has transformed Ebola from a global emergency to a disease that can be stopped in its tracks. This partnership ensures a sustainable vaccine supply for years to come.

Beyond emergency response, the improved vaccine will support preventive vaccination programs for healthcare workers and others at high risk in regions where outbreaks occur. Protecting those on the front lines means faster containment and fewer deaths when Ebola appears.

The project brings together longstanding partners committed to defending against one of humanity's deadliest known pathogens, turning scientific progress into real world protection for the people who need it most.